LOINC
Version 2.67

93851-4Delamanid [Susceptibility]Active

Part Description

LP412105-1   Delamanid
Delamanid is the first in a new class of anti-mycobacterial agents called bicyclic nitroimidazoles. It is indicated for pulmonary multidrug-resistant tuberculosis (MDR-TB) and is effective against Mycobacterium tuberculosis during replication, dormancy, and intracellular stages. It is primarily metabolized by serum albumin, and does not affect cytochrome P450 metabolic activity. In clinical trials, delamanid was associated with prolonged QTc on EKG that peaks at 8 weeks following the start of therapy and resolves within 4 weeks after stopping therapy, but which did not result in any cardiac events. [PMID: 30029909] Source: Regenstrief LOINC

Fully-Specified Name

Component
Delamanid
Property
Susc
Time
Pt
System
Isolate
Scale
OrdQn
Method

Additional Names

Short Name
Delamanid Susc Islt
Display Name
Delamanid [Susc]

Basic Attributes

Class
ABXBACT
Type
Laboratory
First Released
Version 2.67
Last Updated
Version 2.67
Order vs. Observation
Both

LOINC FHIR® API Example - CodeSystem Request Get Info

https://fhir.loinc.org/CodeSystem/$lookup?system=http://loinc.org&code=93851-4